PhRMA Willing To Contribute To Drug ‘Affordability’ – But Mum On How Much
PhRMA CEO Steven Ubl offers list of policy alternatives to drug pricing bills pending in the US Congress that he argues would stifle innovation; industry's plans, on the other hand, could produce "meaningful" legislation.
You may also be interested in...
Arielle Woronoff joins the Biden Administration after four years of steering health policy at the Senate Finance Committee, including work on the Grassley-Wyden bill.
The annual J.P. Morgan Health Care Conference has come to a close. In Vivo has summarized some of the key themes to appear from 2021’s virtual meeting of industry leaders, investors and technology creators.
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Novartis explains its PD-1 deal; Biogen partners with Apple; Sanofi and Merck discuss business development priorities; and why AbbVie is confident it can grow without relying on deals.